HAP

NOTE: You can download the attached FULL PDF

We upgrade our rating to BUY from HOLD based on our increased conviction for compelling Phase II results for TH-302 in combination with standard chemotherapeutics.

• Product Development - Hypoxic Depth Charge - Threshold Pharmaceuticals has preliminary Phase I/II data showing that its TH-302 hypoxia-activated prodrug (HAP) could kill cells in hypoxic regions of tumors where chemotherapy doesn't reach.
From BioCentury - http://www.biocentury.com
 
By Aaron Bouchie
Senior Writer